We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Posttransplant anemia: the role of sirolimus.
- Authors
Fishbane, Steven; Cohen, David J.; Coyne, Daniel W.; Djamali, Arjang; Singh, Ajay K.; Wish, Jay B.
- Abstract
Posttransplant anemia is a common problem that may hinder patients’ quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.Kidney International (2009) 76, 376–382; doi:10.1038/ki.2009.231; published online 24 June 2009
- Subjects
ANEMIA; BLOOD diseases; RAPAMYCIN; IMMUNOSUPPRESSIVE agents; MACROLIDE antibiotics
- Publication
Kidney International, 2009, Vol 76, Issue 4, p376
- ISSN
0085-2538
- Publication type
Article
- DOI
10.1038/ki.2009.231